AMH Equity Ltd Has $2.89 Million Stock Position in Myriad Genetics, Inc. $MYGN

AMH Equity Ltd increased its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 33.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 400,000 shares of the company’s stock after buying an additional 100,000 shares during the period. Myriad Genetics accounts for 3.6% of AMH Equity Ltd’s holdings, making the stock its 7th largest position. AMH Equity Ltd owned 0.43% of Myriad Genetics worth $2,892,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its stake in Myriad Genetics by 2,333.3% in the second quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock valued at $25,000 after buying an additional 4,480 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Myriad Genetics by 6,192.9% in the second quarter. Farther Finance Advisors LLC now owns 5,349 shares of the company’s stock valued at $28,000 after buying an additional 5,264 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Myriad Genetics by 407.3% during the second quarter. Nisa Investment Advisors LLC now owns 5,773 shares of the company’s stock worth $31,000 after buying an additional 4,635 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Myriad Genetics during the second quarter worth $37,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Myriad Genetics by 41.4% during the second quarter. PNC Financial Services Group Inc. now owns 8,967 shares of the company’s stock worth $48,000 after buying an additional 2,625 shares in the last quarter. 99.02% of the stock is owned by institutional investors.

Myriad Genetics Stock Performance

Shares of MYGN opened at $5.92 on Friday. The company has a current ratio of 2.33, a quick ratio of 2.12 and a debt-to-equity ratio of 0.32. Myriad Genetics, Inc. has a 12 month low of $3.76 and a 12 month high of $15.47. The company has a market capitalization of $551.80 million, a price-to-earnings ratio of -1.37 and a beta of 1.81. The stock has a 50 day moving average of $6.76 and a 200 day moving average of $6.57.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. UBS Group boosted their price target on Myriad Genetics from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Wells Fargo & Company lifted their price target on shares of Myriad Genetics from $6.00 to $6.50 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. TD Cowen boosted their price objective on shares of Myriad Genetics from $8.00 to $9.00 and gave the stock a “hold” rating in a research note on Tuesday, November 4th. Cowen reaffirmed a “hold” rating on shares of Myriad Genetics in a research report on Tuesday, November 4th. Finally, Piper Sandler reduced their price target on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.44.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.